Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Urinary Bladder Neoplasms 2Stomatitis 2Squamous Cell Carcinoma of Head and Neck 2Mouth Neoplasms 2Leukemia, Myeloid, Acute 2Brain Neoplasms 2Vulvar Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Tonsillar Neoplasms 1Tongue Neoplasms 1Rectal Neoplasms 1Parotid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligometastatic Malignant Solid Neoplasm 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Maxillary Sinus Neoplasms 1Lymphoma, B-Cell 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Carcinoma 1

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bilateral Breast Carcinoma × Practice Guidelines as Topic × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡